<DOC>
	<DOCNO>NCT00811135</DOCNO>
	<brief_summary>This single arm study ass efficacy safety Avastin combination Herceptin Xeloda first-line treatment patient HER2-positive locally recurrent metastatic breast cancer . Patients receive 3-weekly treatment cycle Herceptin ( 8mg/kg iv day 1 first cycle , follow 6mg/kg iv maintenance dose day 1 subsequent cycle ) , Xeloda ( 1000mg/m2 bid po day 1-14 treatment cycle ) Avastin ( 15mg/kg day 2 first treatment cycle , day 1 subsequent cycle ) .The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Herceptin ( Trastuzumab ) Xeloda ( Capecitabine ) Patients With HER2-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; breast cancer measurable locally recurrent metastatic lesion ; candidate chemotherapy ; HER2positive disease ; ECOG PS &lt; =2 . previous anticancer therapy metastatic breast cancer ; previous radiotherapy metastatic breast cancer ( except adjuvant radiotherapy &gt; =6 month enrollment ) ; chronic daily treatment corticosteroid ( &gt; =10mg/day ) , aspirin ( &gt; 325 mg/day ) clopidogrel ( &gt; 75mg/day ) ; primary tumor within last 5 year , except adequately treated cervical cancer situ , squamous basal cell skin cancer ; uncontrolled hypertension significant cardiovascular disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>